Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$273.15

-1.31 (-0.48%)

(As of 09/18/2024 ET)

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 24 Analyst Ratings

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 7 have given a hold rating, and 17 have given a buy rating for ALNY.

Consensus Price Target

$279.14
2.19% Upside

High Forecast	$400.00
Average Forecast	$279.14
Low Forecast	$159.00

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $279.14. The highest price target for ALNY is $400.00, while the lowest price target for ALNY is $159.00. The average price target represents a forecasted upside of 2.19% from the current price of $273.15.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	11 Buy rating(s)	16 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$279.14	$277.14	$220.12	$247.40
Forecasted Upside	2.19% Upside	13.49% Upside	37.09% Upside	23.42% Upside

Kamala’s Dirty Election Move… Revealed (Ad)

According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…

Click here now and learn how to prepare.

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.19% Upside	1,007.90% Upside	7.93% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/9/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $220.00	-13.52%
9/4/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$300.00 ➝ $300.00	+19.91%
9/4/2024	Bank of America 4 of 5 stars		Boost Target	Buy ➝ Buy	$295.00 ➝ $307.00	+20.97%
8/30/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$400.00 ➝ $400.00	+52.61%
8/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$248.00 ➝ $280.00	+3.37%
8/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$198.00 ➝ $370.00	+40.85%
Kamala’s Dirty Election Move… Revealed (Ad) According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare.
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$207.00 ➝ $233.00	-14.17%
8/2/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$242.00 ➝ $275.00	+2.10%
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$291.00 ➝ $342.00	+24.91%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$291.00 ➝ $295.00	+12.94%
8/2/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$275.00 ➝ $320.00	+19.13%
8/2/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$357.00 ➝ $366.00	+36.26%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$250.00 ➝ $255.00	-3.04%
6/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$253.00 ➝ $288.00	+18.37%
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$215.00 ➝ $295.00	+20.32%
6/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$260.00 ➝ $282.00	+18.57%
6/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$138.00 ➝ $159.00	-33.15%
6/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$210.00 ➝ $260.00	+12.40%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$234.00 ➝ $234.00	+3.28%
5/3/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$225.00 ➝ $225.00	+49.69%
4/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/14/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$210.00 ➝ $217.00	+15.12%
10/11/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$237.00 ➝ $218.00	+28.97%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$220.00	+8.83%
2/21/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$304.00	+48.68%
10/3/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$218.00 ➝ $232.00	+15.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:33 AM ET.

ALNY Forecast - Frequently Asked Questions

What is Alnylam Pharmaceuticals' forecast for 2024?: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $279.14, with a high forecast of $400.00 and a low forecast of $159.00.
Should I buy or sell Alnylam Pharmaceuticals stock right now?: 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
Does Alnylam Pharmaceuticals's stock price have much upside?: According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 13.76% based on their 12-month stock forecasts.
Has Alnylam Pharmaceuticals been upgraded by Wall Street analysts recently?: Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 upgrade by analysts.
What analysts cover Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Needham & Company LLC, Raymond James, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?: Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.71 while the average consensus rating score for "medical" companies is 2.77. Learn more on how ALNY compares to other companies.